

1.	<p><b>Treatment &amp; Condition</b></p> <p>Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer</p>																		
2.	<p><b>Associated appraisal body &amp; Summary of ruling</b></p> <p>NICE Technology Appraisal guidance TA638 (July 2020)</p> <p>Atezolizumab (Tecentriq<sup>®</sup>) with carboplatin and etoposide is recommended as an option for untreated extensive-stage small-cell lung cancer in adults, only if:</p> <ul style="list-style-type: none"> <li>• they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and</li> <li>• the company provides atezolizumab according to the commercial arrangement</li> </ul>																		
3.	<p><b>Number of people in Northern Ireland expected to take up service/therapy</b></p> <p>According to the Resource Impact Template that accompanies, the number of people expected to take up treatment with this regimen in line with this guidance is as follows:</p> <table border="1" data-bbox="261 1081 1445 1323"> <thead> <tr> <th colspan="6" data-bbox="261 1081 1445 1182">Estimated numbers of people treated in Northern Ireland</th> </tr> <tr> <th data-bbox="261 1182 762 1218"></th> <th data-bbox="762 1182 900 1218">2020/21</th> <th data-bbox="900 1182 1035 1218">2021/22</th> <th data-bbox="1035 1182 1171 1218">2022/23</th> <th data-bbox="1171 1182 1308 1218">2023/24</th> <th data-bbox="1308 1182 1445 1218">2024/25</th> </tr> </thead> <tbody> <tr> <td data-bbox="261 1218 762 1323">Estimated number of people treated with atezolizumab with carboplatin and etoposide</td> <td data-bbox="762 1218 900 1323">20</td> <td data-bbox="900 1218 1035 1323">40</td> <td data-bbox="1035 1218 1171 1323">40</td> <td data-bbox="1171 1218 1308 1323">40</td> <td data-bbox="1308 1218 1445 1323">40</td> </tr> </tbody> </table>	Estimated numbers of people treated in Northern Ireland							2020/21	2021/22	2022/23	2023/24	2024/25	Estimated number of people treated with atezolizumab with carboplatin and etoposide	20	40	40	40	40
Estimated numbers of people treated in Northern Ireland																			
	2020/21	2021/22	2022/23	2023/24	2024/25														
Estimated number of people treated with atezolizumab with carboplatin and etoposide	20	40	40	40	40														
4.	<p><b>Patient Access Scheme Availability</b></p> <p>(<u>Yes</u>/No)</p> <p>The company (Roche) has a commercial arrangement. This makes atezolizumab available to the NHS with a discount. The size of the discount is commercial in confidence.</p>																		
5.	<p><b>Infrastructure Requirements</b></p> <p>Any additional infrastructure costs associated with the introduction of new cancer therapies will be dealt with as part of the routine commissioning process.</p>																		
6.	<p><b>Expected implementation period</b></p> <p>There is no impediment to immediate implementation for new patients</p>																		
7.	<p><b>Commissioning arrangements</b></p>																		

	<p>This regimen will be formally commissioned by the HSCB/PHA via the Specialist Services Commissioning Team initially on a cost-per-case (CPC) basis. Thereafter, numbers of patients who received or are receiving treatment will be reviewed and consideration will be given to moving to recurrent funding to support this regimen</p>
<p><b>8.</b></p>	<p><b>Monitoring arrangements</b></p> <p>The HSCB cost per case process will generate quarterly reports on the number of applications.</p> <p>HSCB currently routinely reviews quarterly monitoring information in relation to the usage of all recurrently funded specialist cancer drugs across both the Cancer Centre and other Units.</p> <p>The monitoring pro forma will be adapted to capture information in respect of this regimen and this group of patients. This monitoring report is submitted to the Specialist Services Commissioning Team for formal review and comment by the Team.</p>
<p><b>9.</b></p>	<p><b>DoH (NI) Legislative/Policy Caveats</b></p> <p>This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.</p>